Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: crysball who wrote (951)	7/7/1998 9:48:00 AM
From: Omer Shvili	Read Replies (1) \| Respond to of 1491

PARS has published its work in the important science/neurology publications. The people who need to know (neurologists, big pharmaceuticals companies etc.), allready know that PARS's research is much more advanced than NIH. PARS is allready passed the preclinical stage, and as we all know it is allready in advanced phase II trials for head trauma. In the neurology community, people know what PARS is doing. An article in the N.Y. Times or Washington Post, don't mean that much in the pharmaceuticals community. It is important, however, for us shareholders. Pharmos's management doesn't want to hype the stock, so don't expect an article with a leading paper befor Pharmos has data of, at least, its phase II studies. People in the biotech industry know that an article about preclinical work doesn't mean all that much, and is usualy meant just to hype a stock. A lot of products that looked good in preclinical trials failed in the clinical phases. Think what will happen to ENMD, and its shareholders, if they come out a year from today, saying their cancer program failed in clinical trials. PARS's management is conservative, but they also know what they have on hand. Once we have phase II numbers out, I guess they will be less hesitant to talk to media about the potential of HU211 (assuming the numbers will be good ones). Omer

To: crysball who wrote (951)	7/7/1998 9:19:00 PM
From: arnie h	Read Replies (2) \| Respond to of 1491

Dear crysball: Seems to me the thread is taking a tacking move into the area of background scatter. There are 3 important aspects to PARS these days; sales by Bausch & Lomb, results of the HU 211 trial and it's ramifications, and the actions of the hedge funders with whom we are unfortunately associated. All the other stuff is interesting but won't make a difference at the end of the day. Let's hope we get some real news one of these days that makes a difference. Arnie H